Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA: 600420)

Market Cap	17.03B
Revenue (ttm)	11.50B
Net Income (ttm)	1.08B
Shares Out	1.34B
EPS (ttm)	0.81
PE Ratio	15.73
Forward PE	12.70
Dividend	0.20 (1.61%)
Ex-Dividend Date	Sep 20, 2024

Volume	16,351,592
Open	12.46
Previous Close	12.47
Day's Range	12.20 - 12.62
52-Week Range	7.61 - 14.41
Beta	0.21
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Shanghai Shyndec Pharmaceutical

Shanghai Shyndec Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of pharmaceutical intermediates, raw materials, and pharmaceutical preparations in China and internationally. The company’s pharmaceutical intermediate products primarily includes 7-ACA, 6-APA, penicillin industrial salt, etc.; API products for anti-infection applications comprising azithromycin, amoxicillin, potassium clavulanate, ceftriaxone sodium, etc., as well as urine source biochemical products and other characteristic raw materials; p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1996
• Employees: 11,608
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600420

Financial Performance

In 2023, Shanghai Shyndec Pharmaceutical's revenue was 12.07 billion, a decrease of -6.86% compared to the previous year's 12.96 billion. Earnings were 691.88 million, an increase of 10.21%.